Locally Advanced Kidney Cancer: A New Space for Immunotherapy?

Singla, Nirmish; Margulis, Vitaly

doi:10.1016/j.euo.2021.05.003

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Up to 30 % of patients with RCC are diagnosed at the metastatic phase [ 3 , 9 ]. While immunotherapy is promising, a substantial proportion of patients is resistant [38] . Previously, we have shown that RCC's peritumoral tissue constitutes a reservoir of cytotoxic/migratory NK cells and T cells [16] .…”

Section: Discussionmentioning

confidence: 99%

Distinct leukocyte populations and cytokine secretion profiles define tumoral and peritumoral areas in renal cell carcinoma

Borcinova,

Bartolini,

Foley

et al. 2024

Translational Oncology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Distinct leukocyte populations and cytokine secretion profiles define tumoral and peritumoral areas in renal cell carcinoma

Borcinova,

Bartolini,

Foley

et al. 2024

Translational Oncology

View full text Add to dashboard Cite

“…That PD-1 inhibition may enhance the anti-tumor T cell response induced by the primary tumor while the tumor is still in situ forms the basis to consider neoadjuvant ICI for high risk RCC. As such, our group recently completed a phase I trial demonstrating the safety and feasibility of neoadjuvant nivolumab followed by nephrectomy in 17 patients with non-metastatic high-risk ccRCC 18 , 19 . As the first published prospective trial of its kind, we noted that among 15 evaluable patients, all had stable disease on nivolumab with one (6.7%) demonstrating features of an immune-related pathologic response.…”

Section: Introductionmentioning

confidence: 99%

Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma

Singla,

Nirschl,

Obradovic

et al. 2024

Sci Rep

Self Cite

View full text Add to dashboard Cite

Novel perioperative strategies are needed to reduce recurrence rates in patients undergoing nephrectomy for high-risk, non-metastatic clear cell renal cell carcinoma (ccRCC). We conducted a prospective, phase I trial of neoadjuvant nivolumab prior to nephrectomy in 15 evaluable patients with non-metastatic ccRCC. We leveraged tissue from that cohort to elucidate the effects of PD-1 inhibition on immune cell populations in ccRCC and correlate the evolving immune milieu with anti-PD-1 response. We found that nivolumab durably induces a pro-inflammatory state within the primary tumor, and baseline immune infiltration within the primary tumor correlates with nivolumab responsiveness. Nivolumab increases CTLA-4 expression in the primary tumor, and subsequent nephrectomy increases circulating concentrations of sPD-L1, sPD-L3 (sB7-H3), and s4-1BB. These findings form the basis to consider neoadjuvant immune checkpoint inhibition (ICI) for high-risk ccRCC while the tumor remains in situ and provide the rationale for perioperative strategies of novel ICI combinations.

show abstract

Locally Advanced Kidney Cancer: A New Space for Immunotherapy?

Cited by 2 publications

References 9 publications

Distinct leukocyte populations and cytokine secretion profiles define tumoral and peritumoral areas in renal cell carcinoma

Distinct leukocyte populations and cytokine secretion profiles define tumoral and peritumoral areas in renal cell carcinoma

Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma

Contact Info

Product

Resources

About